Several prospective randomized studies have shown that the treatment of chronic myeloid
leukemia with interferon-(IFN-) prolongs the survival by comparison with conventional …

PURPOSE: To provide a status report on the use of interferon (IFN)-a in patients with chronic
myelogenous leukemia (CML). DATA SOURCES: Data on IFN-a therapy for CML collected …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

Interferon-A (IFN-A) is an effective agent in the treatment of chronic myelogenous leukemia
(CML). Hematologic remissions occur in the majority of patients with newly diagnosed …

In patients with previously untreated chronic myelogenous leukaemia (CML) the efficacy of
single‐agent interferon (IFN)‐alpha at an initial dose of 4 times 106 U/m2 (arm A) was …

131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia
(CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN …

In a single institution, we have used recombinant interferon-(IFN-) to treat 116 newly
diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients and …

Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have
reported better patient survival with interferon alfa (IFN α) than with standard …

Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

Background In view of studies showing that interferon alfa was effective treatment for chronic
myeloid leukemia and that it prolonged survival, we organized a prospective, controlled …